PL3034514T3 - Przeciwciało specyficznie wiążące się z glp-1r i jego białko fuzyjne z glp-1 - Google Patents
Przeciwciało specyficznie wiążące się z glp-1r i jego białko fuzyjne z glp-1Info
- Publication number
- PL3034514T3 PL3034514T3 PL14836776.6T PL14836776T PL3034514T3 PL 3034514 T3 PL3034514 T3 PL 3034514T3 PL 14836776 T PL14836776 T PL 14836776T PL 3034514 T3 PL3034514 T3 PL 3034514T3
- Authority
- PL
- Poland
- Prior art keywords
- glp
- fusion protein
- specifically binding
- antibody specifically
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310350640 | 2013-08-13 | ||
| PCT/CN2014/083568 WO2015021871A1 (zh) | 2013-08-13 | 2014-08-01 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3034514T3 true PL3034514T3 (pl) | 2024-10-07 |
Family
ID=52468032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14836776.6T PL3034514T3 (pl) | 2013-08-13 | 2014-08-01 | Przeciwciało specyficznie wiążące się z glp-1r i jego białko fuzyjne z glp-1 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10059773B2 (pl) |
| EP (1) | EP3034514B1 (pl) |
| JP (1) | JP6749235B2 (pl) |
| KR (1) | KR102285342B1 (pl) |
| CN (1) | CN104371019B (pl) |
| AU (1) | AU2014308330C1 (pl) |
| CA (1) | CA2921256C (pl) |
| ES (1) | ES2988117T3 (pl) |
| IL (1) | IL243902B (pl) |
| PL (1) | PL3034514T3 (pl) |
| RU (1) | RU2681857C2 (pl) |
| TW (1) | TWI568745B (pl) |
| WO (1) | WO2015021871A1 (pl) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI707038B (zh) | 2013-08-05 | 2020-10-11 | 美商扭轉生物科技有限公司 | 重新合成之基因庫 |
| MX2016012124A (es) | 2014-03-19 | 2017-04-06 | Mackay Medical Found The Presbyterian Church In Taiwan Mackay Memorial Hospital | Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos. |
| ES2833099T3 (es) | 2015-02-11 | 2021-06-14 | Gmax Biopharm Llc | Preparación de disolución estabilizada de una proteína de fusión de un anticuerpo de GLP-1R farmacéutica |
| US9981239B2 (en) | 2015-04-21 | 2018-05-29 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
| KR20180050411A (ko) | 2015-09-18 | 2018-05-14 | 트위스트 바이오사이언스 코포레이션 | 올리고핵산 변이체 라이브러리 및 그의 합성 |
| CN108698012A (zh) | 2015-09-22 | 2018-10-23 | 特韦斯特生物科学公司 | 用于核酸合成的柔性基底 |
| WO2017095958A1 (en) | 2015-12-01 | 2017-06-08 | Twist Bioscience Corporation | Functionalized surfaces and preparation thereof |
| US11046782B2 (en) * | 2016-03-30 | 2021-06-29 | Musc Foundation For Research Development | Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination |
| CN107663240B (zh) * | 2016-07-29 | 2021-01-12 | 中国人民解放军第四军医大学 | 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用 |
| KR102212257B1 (ko) | 2016-08-22 | 2021-02-04 | 트위스트 바이오사이언스 코포레이션 | 드 노보 합성된 핵산 라이브러리 |
| WO2018057526A2 (en) | 2016-09-21 | 2018-03-29 | Twist Bioscience Corporation | Nucleic acid based data storage |
| US11219669B2 (en) | 2016-12-15 | 2022-01-11 | Talengen International Limited | Method for preventing and treating liver fibrosis |
| EP3554514A4 (en) | 2016-12-16 | 2020-08-05 | Twist Bioscience Corporation | BANKS OF VARIANTS OF IMMUNOLOGICAL SYNAPSE AND THEIR SYNTHESIS |
| KR102781241B1 (ko) | 2017-01-17 | 2025-03-14 | 암젠 인크 | 위 저해 펩타이드 수용체(gipr)에 대한 길항제에 접합된 glp-1 수용체 작용제를 사용하여 대사 장애를 치료 또는 개선하는 방법 |
| CN110892485B (zh) | 2017-02-22 | 2024-03-22 | 特韦斯特生物科学公司 | 基于核酸的数据存储 |
| AU2018234629A1 (en) | 2017-03-15 | 2019-10-17 | Twist Bioscience Corporation | Variant libraries of the immunological synapse and synthesis thereof |
| WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| JP7169999B2 (ja) | 2017-06-12 | 2022-11-11 | ツイスト バイオサイエンス コーポレーション | シームレス核酸アセンブリのための方法 |
| US11938172B2 (en) | 2017-06-19 | 2024-03-26 | Talengen International Limited | Method for regulating and controlling GLP-1/GLP-1R and drug |
| AU2018328847A1 (en) | 2017-09-11 | 2020-04-23 | Twist Bioscience Corporation | GPCR binding proteins and synthesis thereof |
| JP7239566B2 (ja) * | 2017-09-22 | 2023-03-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 |
| WO2019079769A1 (en) | 2017-10-20 | 2019-04-25 | Twist Bioscience Corporation | HEATED NANOWELLS FOR THE SYNTHESIS OF POLYNUCLEOTIDES |
| EP4715681A2 (en) | 2018-01-04 | 2026-03-25 | Atlas Data Storage, Inc. | Dna-based digital information storage |
| CN117003874A (zh) * | 2018-03-20 | 2023-11-07 | 鸿运华宁（杭州）生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| CN110357959B (zh) | 2018-04-10 | 2023-02-28 | 鸿运华宁（杭州）生物医药有限公司 | Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| IL278771B2 (en) | 2018-05-18 | 2025-09-01 | Twist Bioscience Corp | Polynucleotides, reagents and methods for nucleic acid hybridization |
| CN119613548A (zh) * | 2018-06-13 | 2025-03-14 | 鸿运华宁（杭州）生物医药有限公司 | APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用 |
| WO2020139871A1 (en) | 2018-12-26 | 2020-07-02 | Twist Bioscience Corporation | Highly accurate de novo polynucleotide synthesis |
| AU2020227802A1 (en) | 2019-02-26 | 2021-10-14 | Twist Bioscience Corporation | Variant nucleic acid libraries for antibody optimization |
| WO2020176678A1 (en) | 2019-02-26 | 2020-09-03 | Twist Bioscience Corporation | Variant nucleic acid libraries for glp1 receptor |
| CA3144644A1 (en) | 2019-06-21 | 2020-12-24 | Twist Bioscience Corporation | Barcode-based nucleic acid sequence assembly |
| CN112239507A (zh) | 2019-07-17 | 2021-01-19 | 鸿运华宁（杭州）生物医药有限公司 | ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用 |
| CN112521501A (zh) * | 2019-09-18 | 2021-03-19 | 鸿运华宁（杭州）生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| EP4034564A4 (en) | 2019-09-23 | 2023-12-13 | Twist Bioscience Corporation | VARIANT NUCLEIC ACID LIBRARIES FOR SINGLE-DOMAIN ANTIBODIES |
| US12091777B2 (en) | 2019-09-23 | 2024-09-17 | Twist Bioscience Corporation | Variant nucleic acid libraries for CRTH2 |
| PL4071171T3 (pl) | 2019-12-06 | 2025-09-22 | Korea Atomic Energy Research Institute | Przeciwciało anty-tm4sf4 i jego zastosowanie |
| BR112022011235A2 (pt) | 2019-12-09 | 2022-12-13 | Twist Bioscience Corp | Bibliotecas de variantes de ácido nucleico para receptores de adenosina |
| GB202011958D0 (en) * | 2020-07-31 | 2020-09-16 | Pole Jolene | The facelet |
| MX2023002974A (es) | 2020-09-14 | 2023-05-25 | Regeneron Pharma | Conjugados de anticuerpo-farmaco que comprenden peptidomimeticos glp1 y usos de los mismos. |
| US12122817B2 (en) * | 2020-09-22 | 2024-10-22 | Serpentide Inc. | Long-lasting GLP1 analogue drug for type-2 diabetes |
| WO2022271258A1 (en) * | 2021-06-25 | 2022-12-29 | La Jolla Institute For Immunology | Chimeric anti-sars-cov2 nucleoprotein antibodies |
| EP4416184A4 (en) * | 2021-10-11 | 2025-11-19 | Ohio State Innovation Foundation | Glycoprotein Predominantly Repeating Antibodies (GARP) and Their Uses |
| AU2023231305A1 (en) * | 2022-03-11 | 2024-09-12 | Regeneron Pharmaceuticals, Inc. | Anti-GLP1r antibody-tethered drug conjugates comprising GLP1 peptidomimetics and uses thereof |
| KR20250075642A (ko) | 2022-09-21 | 2025-05-28 | 리제너론 파아마슈티컬스, 인크. | 비만, 당뇨병 및 간 기능 장애를 치료하는 방법 |
| WO2025147573A2 (en) | 2024-01-05 | 2025-07-10 | Immusoft Corporation | Glp-1 expressing modified b cells for the treatment of metabolic disease |
| CN119684460B (zh) * | 2024-12-27 | 2026-04-03 | 上海百英生物科技股份有限公司 | 一种抗glp-1r纳米抗体、其制备方法及其应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9409496D0 (en) | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
| US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
| US6277819B1 (en) | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| SE9802080D0 (sv) | 1998-06-11 | 1998-06-11 | Hellstroem | Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein |
| US5899883A (en) | 1998-07-08 | 1999-05-04 | Jinq Shing Chern | Safety syringe |
| AU5027299A (en) | 1998-07-31 | 2000-02-28 | Novo Nordisk A/S | Use of glp-1 and analogues for preventing type ii diabetes |
| MY155270A (en) | 1998-09-24 | 2015-09-30 | Lilly Co Eli | Use of glp-1 or analogs in treatment of stroke |
| ES2311560T3 (es) | 2000-12-07 | 2009-02-16 | Eli Lilly And Company | Proteinas de fusion glp-1. |
| TW200530269A (en) * | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
| EA011583B1 (ru) | 2004-03-31 | 2009-04-28 | Сентокор, Инк. | Миметические антитела glp-1 человека, композиции, способы и применения |
| BRPI0518761A2 (pt) * | 2004-12-02 | 2008-12-09 | Domantis Ltd | fusço de droga, conjugado de droga, Ácido nucleico recombinante, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir uma fusço de droga, composiÇço farmacÊutica, droga, mÉtodo de tratamento e/ou prevenÇço de uma condiÇço em um paciente, mÉtodo de retardo ou prevenÇço de progressço de doenÇa, e, mÉtodo para diminuir a absorÇço de alimentos por um paciente |
| PT1831252E (pt) | 2004-12-22 | 2009-09-17 | Lilly Co Eli | Formulações de proteínas de fusão de análogos de glp-1 |
| US20060275288A1 (en) | 2005-01-20 | 2006-12-07 | Grihalde Nelson D | GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof |
| RS51319B (sr) | 2005-09-22 | 2010-12-31 | Biocompatibles Uk Limited | GLP-l (GLUKAGON-LIKE PEPTID-l) FUZIONI POLIPEPTIDI SA POVEĆANOM OTPORNOSTI NA PEPTIDAZE |
| US20090098130A1 (en) | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| RU2432361C2 (ru) * | 2007-01-05 | 2011-10-27 | КовЭкс Текнолоджиз Айэлэнд Лимитед | Соединения агонисты рецептора глюкагоноподобного белка-1 (glp-1r) |
| CN101663317A (zh) * | 2007-01-05 | 2010-03-03 | CovX科技爱尔兰有限公司 | 胰高血糖素样蛋白-1受体glp-1r激动剂化合物 |
| US20090021453A1 (en) | 2007-07-19 | 2009-01-22 | Zachary Smith | Fashion accessory including alternating light emitting and non-light emitting elements of consistent lengths |
| US7982016B2 (en) * | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| JP2011503000A (ja) * | 2007-11-02 | 2011-01-27 | セントコア・オーソ・バイオテツク・インコーポレーテツド | 半合成ＧＬＰ−１ペプチド−Ｆｃ融合コンストラクト、その方法及び使用 |
| KR20100132535A (ko) * | 2008-03-31 | 2010-12-17 | 글락소 그룹 리미티드 | 약물 융합체 및 컨주게이트 |
| US20120058116A1 (en) * | 2009-04-24 | 2012-03-08 | Andrew Beaton | Fgfr1c antibody combinations |
| WO2011056644A2 (en) * | 2009-10-28 | 2011-05-12 | Centocor Ortho Biotech Inc. | Anti-glp-1r antibodies and their uses |
| EP2501367B1 (en) | 2009-11-17 | 2015-01-21 | Ipsen Pharma S.A.S. | Formulation for HGH and RHIGF-1 combination |
| JP5899883B2 (ja) | 2011-01-26 | 2016-04-06 | セントラル硝子株式会社 | 高圧ガスの供給方法、衝撃波減衰機構を有する機器及び高圧ガスの供給装置 |
| TW201249867A (en) * | 2011-04-01 | 2012-12-16 | Astellas Pharma Inc | Novel anti-human il-23 receptor antibody |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| JP6006753B2 (ja) | 2014-07-08 | 2016-10-12 | 株式会社京三製作所 | 踏切保安システム、中央装置及び踏切制御装置 |
-
2014
- 2014-07-22 CN CN201410349725.1A patent/CN104371019B/zh active Active
- 2014-08-01 ES ES14836776T patent/ES2988117T3/es active Active
- 2014-08-01 PL PL14836776.6T patent/PL3034514T3/pl unknown
- 2014-08-01 JP JP2016533798A patent/JP6749235B2/ja active Active
- 2014-08-01 RU RU2016108703A patent/RU2681857C2/ru active
- 2014-08-01 AU AU2014308330A patent/AU2014308330C1/en active Active
- 2014-08-01 CA CA2921256A patent/CA2921256C/en active Active
- 2014-08-01 KR KR1020167003696A patent/KR102285342B1/ko active Active
- 2014-08-01 US US14/911,715 patent/US10059773B2/en active Active
- 2014-08-01 EP EP14836776.6A patent/EP3034514B1/en active Active
- 2014-08-01 WO PCT/CN2014/083568 patent/WO2015021871A1/zh not_active Ceased
- 2014-08-13 TW TW103127846A patent/TWI568745B/zh active
-
2016
- 2016-02-01 IL IL243902A patent/IL243902B/en active IP Right Grant
-
2018
- 2018-08-13 US US16/102,552 patent/US10253103B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016108703A (ru) | 2017-09-14 |
| CA2921256A1 (en) | 2015-02-19 |
| AU2014308330B2 (en) | 2020-02-13 |
| US10059773B2 (en) | 2018-08-28 |
| NZ716357A (en) | 2022-03-25 |
| RU2681857C2 (ru) | 2019-03-13 |
| AU2014308330A2 (en) | 2016-04-28 |
| US20180346585A1 (en) | 2018-12-06 |
| TWI568745B (zh) | 2017-02-01 |
| RU2016108703A3 (pl) | 2018-03-19 |
| EP3034514A4 (en) | 2017-11-01 |
| US10253103B2 (en) | 2019-04-09 |
| US20160362498A1 (en) | 2016-12-15 |
| EP3034514A1 (en) | 2016-06-22 |
| KR102285342B1 (ko) | 2021-08-03 |
| AU2014308330C1 (en) | 2020-05-07 |
| EP3034514B1 (en) | 2024-07-17 |
| CN104371019A (zh) | 2015-02-25 |
| TW201514205A (zh) | 2015-04-16 |
| IL243902A0 (en) | 2016-04-21 |
| CN104371019B (zh) | 2019-09-10 |
| HK1226415A1 (en) | 2017-09-29 |
| JP2016532448A (ja) | 2016-10-20 |
| JP6749235B2 (ja) | 2020-09-16 |
| WO2015021871A1 (zh) | 2015-02-19 |
| CA2921256C (en) | 2023-02-21 |
| IL243902B (en) | 2020-06-30 |
| KR20160055789A (ko) | 2016-05-18 |
| ES2988117T3 (es) | 2024-11-19 |
| AU2014308330A1 (en) | 2016-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL243902B (en) | An antibody that specifically binds to glp-1r and its fusion protein with glp-1 | |
| IL269226A (en) | Antibodies that bind to TL1A and uses thereof | |
| IL240034B (en) | and "pd-l1/trail" fusion protein preparation | |
| IL244108A0 (en) | gitr antigen binding proteins | |
| IL240838A0 (en) | Anti-3–lag binding proteins | |
| IL240915A0 (en) | Dual-specific binding proteins directed against tnfɑ | |
| PL2992010T3 (pl) | Modyfikowane asymetryczne przeciwciała wiążące receptor Fc i sposoby ich stosowania | |
| PL3020731T3 (pl) | Nowe podwójnie nakierowane białko specyficznie wiążące się z dll4 i vegf oraz zastosowanie tego białka | |
| SG11201505762XA (en) | Il-11r binding proteins and uses thereof | |
| EP2855533A4 (en) | METHODS RELATING TO CTLA4-FC FUSION PROTEINS | |
| IL246371A0 (en) | Antibodies containing extensions and couplings at the c-terminus of the light polypeptide chain and methods of their use | |
| IL244588B (en) | fusion protein | |
| EP3000825A4 (en) | Trans-tumoral peptide specific to neuropilin and fusion protein having same peptide fused therein | |
| IL240474A0 (en) | Cross-linking proteins that bind to cartilage | |
| EP2969009A4 (en) | MODIFIED FC FUSION PROTEINS | |
| GB201321938D0 (en) | Pesticidal fusion protein improvements | |
| ZA201505509B (en) | Insulinotropic peptide derivative with modified n-terminal charge | |
| GB201320408D0 (en) | Antibody polypeptides and uses therof | |
| IL234394A0 (en) | Recombinant antibodies with dual specificity for gangliosides and their use | |
| EP3029071A4 (en) | Saxatilin-fc fusion protein and use thereof | |
| AU2013901331A0 (en) | Fusion Proteins and Use Thereof | |
| GB201316665D0 (en) | Non-Human Growth Hormone fusion proteins | |
| AU2013901678A0 (en) | Antigenic polypeptides and antibodies thereto |